Illumina, Inc. Stock 12‑Month Price Target Cut to $264.84, Implies 11% Upside

Analysts lowered Illumina's average price target from $267.47 to $264.84, with a range of $196 to $365. This implies an 11% upside from the Nov. 3 close. The consensus rating remains 'Buy' among 24 analysts, with 10 Buys, 10 Holds, and 4 Sells.

Original reporting
Published Nov 4, 2026, 10:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Illumina, Inc. Stock 12‑Month Price Target Cut to $264.84, Implies 11% Upside — source image
Decision brief

The 30-second read

$ILMNBearishLow
01

Why it matters

The slight downgrade may trigger short‑term selling pressure, though the consensus rating stays positive, limiting the move.

02

Market read

The price‑target cut is a modest, new piece of information that could influence short‑term trading decisions for Illumina.

03

What to watch

No new product or earnings data accompanies the target change, so the cut may reflect broader market risk aversion rather than company‑specific issues.

Relevance 6/10Novelty 5/10Timing: pre‑market today

Background

Illumina is a leading provider of DNA sequencing and genomic analysis tools. Analyst consensus remains a Buy, but the average price target slipped slightly.

Company-level read

Ticker impact

$ILMNBearishMedium confidence
Context

Analysts lowered Illumina's average 12‑month price target to $264.84, down from $267.47.

Expected impact

downward pressure as the market prices in the lower target

Evidence & confidence

A modest target reduction without new fundamental data typically leads to short‑term price weakness.

Market effects

Minor impact on the genomics/diagnostics sector as peers may be re‑rated similarly.

Limited to U.S. biotech investors; no broader regional effect.

Low global relevance; primarily affects Illumina shareholders.

Counterpoint

Some investors may view the modest cut as a buying opportunity given the still‑present 11% upside.

Key entities

  • Illumina, Inc.

    US‑listed genomics firm (ticker ILMN).

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.